Randeep Suneja, MD
Interventional Cardiology · Katy, TXNPI 1225198377
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by AstraZeneca at 30.4% of the total. Reporting peaked in 2021 at $8,993 and has fallen 82.7% since, to $1,555 in 2025.
Across 508 payments — averaging $50.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Esperion Therapeutics, Inc.$7K
- Novartis$2K
- Johnson & Johnson$927
- Amgen$736
- Merck$587
- plus $6K from 40 others
Across 5 payments — averaging $3354.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$15K
- Boehringer Ingelheim$1K
- Janssen Research & Development, LLC$500
What the payments were for
- Consulting fees$1,3635%
- Speaking & faculty fees$14,18156%
- Food & beverage$9,92539%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$7,342
- NEXLIZET$7,165
- NEXLETOL$7,165
- LEQVIO$1,512
- Repatha$249
- Cleerly Ischemia$220
- Cleerly Labs$220
- CARDIOMEMS$149
- REZDIFFRA$149
- WATCHMAN Access System$148
- Sotalol Hydrochloride$123
- COMET$103
How this compares
$25,550 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 612 | $795,499 |
| EntrestoSacubitril/Valsartan | 272 | $313,998 |
| XareltoRivaroxaban | 240 | $259,387 |
| FuroscixFurosemide | 30 | $213,680 |
| Repatha SureclickEvolocumab | 164 | $177,296 |
| Praluent PenAlirocumab | 55 | $56,078 |
| VascepaIcosapent Ethyl | 68 | $51,172 |
| Repatha SyringeEvolocumab | 31 | $44,200 |
| Metoprolol Succinate | 2,060 | $32,859 |
| Ezetimibe | 1,068 | $31,405 |
| BrilintaTicagrelor | 36 | $25,953 |
| FarxigaDapagliflozin Propanediol | 24 | $24,442 |
| NexletolBempedoic Acid | 22 | $21,807 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $21,312 |
| EdarbiAzilsartan Medoxomil | 43 | $21,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $365 | $795,499612 claims |
| NovartisEntresto | $2,103 | $313,998272 claims |
| Johnson & JohnsonXarelto | $927 | $259,387240 claims |
| Scpharmaceuticals Inc.Furoscix | $155 | $213,68030 claims |
| AstraZenecaBrilinta, Farxiga | $7,777 | $50,39560 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $7,415 | $43,11843 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $88 | $29,63756 claims |
| Boehringer IngelheimJardiance | $274 | $20,67316 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $176 | $13,24114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Katy
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.